13 results about "Poxvirus Infections" patented technology

The present invention relates to 2'-fluoro-6'-methylene carbocyclic nucleosides and nucleotides, pharmaceutical compositions containing these nucleosides and nucleotides, and their use in the treatment or prophylaxis of poxvirus infections and secondary disease states and conditions thereof.

The present disclosure relates generally to vaccines against orthopoxviruses, and methods for making and using such vaccines. In particular, in some embodiments, the present disclosure relates to nanoparticle-derived vaccines, and compositions based thereon, that elicit an immune response against an orthopoxvirus. The present disclosure further relates to the use of vaccines and vaccine compositions for preventing; decreasing the severity, morbidity and / or mortality of; shortening the duration of; and / or reducing the symptoms of, a poxvirus infection, such as, for example, an orthopoxvirus infection.

This invention discloses a monkeypox virus nanoparticle vaccine based on an HBc-VLP vector, its preparation method, and its application, belonging to the field of biomedical technology. The vaccine uses HBc-VLP as a backbone with SpyCatcher sites on its surface. Through a SpyTag / SpyCatcher coupling system, antigenic polypeptides derived from the monkeypox virus M1R protein (containing overlapping epitopes for B cells and T cells) are loaded onto the VLP surface in a high-density, directed, and stable manner. This design mimics the structure of natural viral particles and can efficiently activate humoral and cellular immunity. The epitopes, screened by immunoinformatics, exhibit high antigenicity, broad-spectrum HLA affinity, and are non-toxic and non-sensitizing. This invention also provides an immunomodulatory composition containing this vaccine and its application in the preparation of drugs for the prevention or treatment of monkeypox virus infection. The vaccine preparation process is simple, has strong antigen compatibility, and has good industrialization prospects.

An immunoassay is described that enables a precise evaluation of immune responses in individuals exposed to Mpox or vaccinated with MVA, with high sensitivity and specificity. The serological assay targets three Orthopoxvirus antigens, MPXV-B6R, MPXV-A27L, and VACV-B5R, which are sufficient to quantify antibody responses to both MVA-vaccination (VACV-B5R) and, separately, infection (MPXV-B6R). The three antigen titres can be combined in a simple function [sum of ((MPXV-B6R) / VACV-B5R) and (MPXV-A27L)] to provide a numerical test score that can be compared with a reference (threshold) value to differentiate between post infection and post vaccination immune responses.

The invention discloses an application of a compound in preparation of a product for resisting poxvirus infection. The compound is PKM2-IN-1. It is clear that PKM2-IN-1 has a remarkable broad-spectrum anti-poxvirus effect for the first time, safety is good, replication of the poxvirus is effectively inhibited, and a new clinical treatment means is provided for preventing and treating diseases caused by the poxvirus.

Provided herein are antibodies and functional fragments thereof for treating or preventing viral diseases, for example pox viral diseases, for example smallpox and monkey pox. Any antibody or functional fragment thereof described herein can be an engineered antibody or engineered antibody fragment. Also, provided herein are compositions and pharmaceutical compositions containing one or more antibodies or functional fragments thereof. Further provided herein are kits containing one or more antibodies or functional fragments thereof, and methods, dosing schedules, dosage amounts, and routes of administration of antibodie(s) and functional fragment(s) thereof. Finally are provided methods of making antibodies and functional fragments thereof.

The current disclosure includes a modular vaccine platform. Also included are monkeypox vaccines that protect against pathogenic monkeypox (Mpox) species, as well as their variants. The vaccines typically include a modified mRNA encoding at least one immunogen, such as a viral envelope protein, cell surface binding protein, or a biologically effective / significant fragment thereof. The mRNA can be encapsulated into lipid nanoparticles or other carriers and formulated as pharmaceutical compositions that can be used to generate an immune response to pathogens, including monkeypox virus, in a subject.

The invention relates to application of apigenin in preparation of a medicine for preventing and / or treating monkey pox virus infection, and belongs to the technical field of biological medicine. A natural product apigenin is selected, the anti-monkey pox virus activity of the apigenin is researched, and the result shows that the apigenin can effectively inhibit expression and replication of monkey pox viruses in host cells in vitro and shows remarkable antiviral activity. In addition, the apigenin is wide in source and low in cost, a new choice is provided for preparation of the anti-monkey pox virus medicine, and the apigenin has good popularization and application prospects.

The application relates to the technical field of biological medicine, and particularly discloses an anti-positive poxvirus monoclonal antibody and application thereof. The anti-positive poxvirus monoclonal antibody provided by the application is 4H4, 12C3 or 11C9. The anti-positive poxvirus monoclonal antibody provided by the application can specifically recognize and target monkeypox, vaccinia and other positive poxviruses, and shows high virus neutralization capacity, and can be used for preparing a medicine for preventing and / or treating positive poxvirus infection and / or a disease related to positive poxvirus infection, or preparing a detection product for detecting positive poxviruses and diagnosing a disease related to positive poxvirus infection.

The invention discloses application of TMEM33 as a target spot in preparation of a product for resisting poxvirus infection. By constructing a knockout cell model and an overexpression cell model, it is clear that TMEM33 is a key target spot for resisting poxvirus infection, and the expression of TMEM33 is improved, so that poxvirus replication is remarkably inhibited. The invention provides technical support for developing novel anti-poxvirus infection related products, and has wide application prospects.

The invention discloses an anti-orthopoxvirus antibody or an antigen binding fragment thereof and application of the anti-orthopoxvirus antibody or the antigen binding fragment. The antibody or the antigen binding fragment thereof can specifically recognize and target orthopoxvirus, and shows efficient virus neutralizing capability; the clinical application value of preventing and treating orthopoxvirus infection is realized; the compound can be used for detecting orthopoxvirus, diagnosing diseases related to orthopoxvirus infection and preventing and / or treating orthopoxvirus infection and / or diseases related to orthopoxvirus infection.

The application discloses a humanized antibody for poxvirus membrane-associated protein L1R and application thereof. An amino acid sequence of a heavy chain variable region of the humanized antibody is shown as SEQ ID No. 1, and an amino acid sequence of a light chain variable region is shown as SEQ ID No. 2. Experiments prove that the humanized antibody provided by the application can efficiently neutralize vaccinia virus and monkeypox virus in an in-vitro experiment, and in an in-vivo protection experiment, the antibody injected in advance can completely protect mice from death caused by vaccinia virus infection. In addition, the humanized antibody provided by the application is the best monoclonal antibody among currently reported poxvirus non-complement-dependent neutralizing antibodies, and has great potential in treatment and prevention of poxvirus infection.

Provided herein are methods for preventing an mpox virus infection, reducing the effects of an mpox virus infection, or inducing a protective immune response against an mpox virus in a subject, such as a human, comprising administering to the subject a pharmaceutical composition comprising a modified vaccinia Ankara viral vector encoding programmed cell death protein 1 (PD-1) inhibitory peptide LD10 (MVA-LD10).